| Literature DB >> 34278210 |
Jayshree South1, Tina Gao1, Andrew Collins1, Arier Lee1, Jason Turuwhenua1, Joanna Black1.
Abstract
PURPOSE: Clinically, aniseikonia (a perceived difference in shape and image size between the eyes) is often neglected in anisometropic amblyopia due to assumed measurement difficulties. Therefore, we currently lack evidence on whether correction of aniseikonia is beneficial. This study aimed to determine whether subjective aniseikonia is measurable in anisometropia with or without amblyopia.Entities:
Keywords: Amblyopia; Aniseikonia; Anisometropia; Binocular Vision; Suppression
Year: 2020 PMID: 34278210 PMCID: PMC8269785 DOI: 10.22599/bioj.154
Source DB: PubMed Journal: Br Ir Orthopt J ISSN: 1743-9868
Participant characteristics and aniseikonia test results.
| Anisometropic Amblyopia Group | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Group | Participant Age (Y) | LogMAR Acuity | Cover Test | Bagolini Striated Glasses | Stereopsis (secs/arc) | Signed Anisometropia (D)* | SE Refractive Error | Method of refractive correction | RT (%) | AI3 (%) | NAT (%) | CAT (%) | ||
| RVA | LVA | |||||||||||||
| AA03 | 52 | 0.50 | 0.00 | 2 xp | BSV | 400 | 4.88 | 5.88 | 1 | Contact lenses with glasses for reading add | –0.60 | –1.48 | 1.01 | 0.42 |
| AA04 | 18 | –0.10 | 0.30 | Micro | Central Suppression | Nil | 5.38 | –0.5 | 4.88 | Trial frames | – | – | 10.00 | 3.52 |
| AA05 | 15 | –0.10 | 0.70 | Micro | L Suppression | Nil | 5.75 | –0.25 | 5.5 | Trial frames | 1.79 | 3.50 | 3.00 | 0.05 |
| AA10 | 23 | 0.20 | –0.10 | 6 xp | BSV | 600 | 4.75 | 2.5 | –2.25 | Trial frames | 6.82 | 10.50 | 6.38 | 7.05 |
| AA16 | 22 | –0.10 | 0.60 | Micro | Central Suppression | 200 | 3.75 | 0.5 | 4.25 | Trial frames | 1.82 | 6.00 | 2.00 | 1.76 |
| AA17 | 20 | –0.20 | 0.30 | Ortho | BSV | 800 | 2.00 | 0.5 | 2.5 | Trial frames | 4.33 | –1.50 | 0.00 | 2.39 |
| AA19 | 22 | –0.10 | 0.20 | Ortho | BSV (with int supp @times) | 100 | 2.00 | 0 | 2 | Habitual Glasses | –0.50 | 1.50 | 2.00 | 2.06 |
| AC02 | 28 | –0.10 | 0.10 | Ortho | BSV | 100 | 3.00 | 2.13 | 5.13 | Trial frames | 4.53 | 1.52 | 0.00 | –1.13 |
| AC11 | 22 | –0.20 | –0.20 | 4 xp | BSV | 40 | 3.25 | –3.25 | –0.75 | Contact lenses | 0.32 | 1.52 | –3.00 | –0.39 |
| AC13 | 28 | –0.10 | –0.10 | 4 xp | BSV | 40 | –1.50 | –0.38 | –1.88 | Habitual Glasses | 1.75 | 0.00 | –1.00 | –3.29 |
| AC14 | 28 | 0.00 | 0.10 | 1 xp | BSV | 40 | –3.25 | –3.38 | –6.63 | Trial frames | –0.23 | –1.50 | 0.00 | 0.84 |
| AC18 | 46 | –0.10 | 0.00 | 12 xp | BSV | 40 | –1.63 | –0.38 | –2 | Trial frames | 0.63 | –1.70 | 1.00 | –0.65 |
| AC23 | 21 | –0.10 | –0.10 | Ortho | BSV | 40 | 2.50 | –2.5 | 0 | Habitual Glasses | 1.99 | –1.50 | –1.00 | –0.09 |
| IC01 | 31 | –0.10 | –0.10 | 1 xp | BSV | 40 | 0.63 | –5.38 | –4.75 | Habitual Glasses | –0.51 | –1.50 | –1.00 | –0.79 |
| IC07 | 38 | 0.10 | –0.10 | Ortho | BSV | 40 | 0.25 | 0 | –0.25 | No ref correction | 0.01 | 0.50 | 0.00 | –0.32 |
| IC08 | 23 | 0.10 | –0.10 | Ortho | BSV | 40 | 0.13 | –0.25 | –0.38 | No ref correction | 0.12 | 2.56 | 1.01 | 0.14 |
| IC15 | 28 | –0.10 | –0.10 | Ortho | BSV | 40 | 0.00 | –0.5 | –0.5 | Trial frames | 0.00 | –0.50 | 0.00 | 0.09 |
| IC20 | 19 | –0.20 | –0.20 | 1 xp | BSV | 40 | 0.00 | –2.38 | –2.38 | Habitual Glasses | 0.00 | 0.50 | 1.00 | –0.92 |
| IC22 | 21 | 0.00 | 0.00 | ortho | BSV | 60 | 0.75 | –0.75 | –1.5 | Contact Lenses | 0.00 | –0.50 | 1.01 | 3.28 |
* Anisometropia was calculated to match the signed percentage of aniseikonia using the following formula: (SENdE = Spherical Equivalent Non dominant Eye, SEDE = Spherical Equivalent Dominant Eye).
AA = Anisometropia Amblyopia, AC = Anisometropic Control, IC = Isometropic Control.
Figure 1(a–c) Inter-test Reliability in 3 Study Groups. Showing greatest amount of aniseikonia in the Anisometropic Amblyopia Group.
Range of aniseikonia per test for the 3 study groups.
| AI3 | NAT | CAT | RT | |
|---|---|---|---|---|
| –1.50% to +10.50% | +0.02% to +10.00% | +0.05% to +7.00% | –0.60% to 6.82% | |
| –1.70% to +1.99% | –3.00% to +1.00 % | –3.29% to +0.84% | –0.23% to 4.53% | |
| –1.50% to +2.56% | –1.00% to +1.00% | –0.92% to 3.28% | –0.51 to 0.1% | |
Figure 2(a–f) Bland-Altman plots for repeated measurements of the four aniseikonia tests. The central solid red line shows the mean difference and the upper and lower broken lines show the 95% limits of agreement.
Figure 3Amount of Aniseikonia versus signed anisometropia.
Results of Bland-Altman analysis for repeated measurements and Pearson correlation values of the four aniseikonia tests.
| Bland Altman results for repeated measures of the four aniseikonia tests | Pearson Correlation Coefficient values | |||
|---|---|---|---|---|
| Test | Mean Difference (%) | 95% limits of agreement (%) | R -values | P-value |
| AI3 vs. NAT | 0.52 | –3.94 to 5.00 | 0.679 | 0.002 |
| AI3 vs. CAT | 0.71 | –4.53 to 5.95 | 0.536 | 0.022 |
| AI3 vs. RT | –0.08 | –4.86 to 4.71 | 0.618 | 0.006 |
| NAT vs. CAT | 0.52 | –3.62 to 4.66 | 0.689 | 0.001 |
| NAT vs. RT | –0.60 | –4.87 to 3.67 | 0.432 | 0.073 |
| CAT vs. RT | –0.79 | –5.27 to 3.70 | 0.434 | 0.072 |